UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                          ---------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                        SECURITIES EXCHANGE ACT OF 1934


                               SEPTEMBER 14, 2004
                Date of Report (Date of earliest event reported)


                          DISCOVERY LABORATORIES, INC.
             (Exact name of Registrant as specified in its charter)


         DELAWARE                   000-26422                94-3171943
      (State or other       (Commission File Number)        (IRS Employer
       jurisdiction                                    Identification Number)
     of incorporation)


                           350 MAIN STREET, SUITE 307
                         DOYLESTOWN, PENNSYLVANIA 18901
                    (Address of principal executive offices)


                                 (215) 340-4699
              (Registrant's telephone number, including area code)


         (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)
[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)
[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))
[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS On September 14, 2004, Discovery Laboratories, Inc. (the "Company") appointed W. Thomas Amick to its Board of Directors. Prior to his appointment as a member of the Board, Mr. Amick served as a commercialization strategist to the Company since March 1, 2004. In such role, Mr. Amick received cash compensation of $60,000 and options to purchase 25,000 shares of common stock of the Company pursuant to the terms and conditions of the Company's 1998 Amended and Restated Stock Incentive Plan. The Company issued a press release announcing Mr. Amick's appointment on September 14, 2004. The full text of the press release is set forth in Exhibit 99.1 hereto. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits: 99.1 Press Release dated September 14, 2004. 2

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISCOVERY LABORATORIES, INC. By: /s/ Robert J. Capetola, -------------------------------- Name: Robert J. Capetola, Ph.D. Title: President and Chief Executive Officer Date: September 20, 2004 3

                                                                    EXHIBIT 99.1


           W. THOMAS AMICK, FORMER J&J SENIOR EXECUTIVE, APPOINTED TO
                       DISCOVERY LABS' BOARD OF DIRECTORS

DOYLESTOWN,  PA -- SEPTEMBER 14, 2004 -- DISCOVERY  LABORATORIES,  INC. (NASDAQ:
DSCO),  today  announced  the  appointment  of W.  Thomas  Amick to its Board of
Directors. Mr. Amick adds global commercial and strategic expertise to Discovery
as the Company prepares for the potential commercialization of its lead product,
Surfaxin(r),  for the  prevention  of  Respiratory  Distress  Syndrome  (RDS) in
premature infants and advances its pipeline of Surfactant  Replacement Therapies
for the treatment of various respiratory diseases.

Mr.  Amick  brings  more  than 30  years  of  pharmaceutical  and  biotechnology
experience as an executive  with Johnson & Johnson,  with specific  expertise in
building and leading commercial  operations throughout North America and Europe.
Mr.  Amick's   positions   included   President  of  Ortho  Biotech  Europe  and
Janssen-Ortho Canada and Worldwide Vice President of J&J's Oncology Group, where
he created and managed the  commercial  organizations  for J&J's first  oncology
franchise within Ortho Biotech.  Mr. Amick was also responsible for building the
organization  that  drove  the  growth  of  Procrit  into a  multibillion-dollar
product.

Robert J. Capetola,  Ph.D.,  President and Chief Executive  Officer of Discovery
Laboratories  stated,  "Tom brings to Discovery's Board extensive  experience in
the commercialization of several  successfully-marketed  products, many of which
set new treatment  standards or established new treatment paradigms within their
therapeutic   areas.   This   experience   is   beneficial   to  executing   our
commercialization  strategy. If approved,  Surfaxin will represent a significant
opportunity  to improve the  standard of care for  premature  infants who suffer
from RDS."

"Discovery's   mission  is  to  advance  to  market  a  pipeline  of  Surfactant
Replacement  Therapies  which we believe  will  revolutionize  the  treatment of
respiratory  diseases.  The  introduction  of  Surfaxin  has  the  potential  to
represent a dramatic  evolution in the role  surfactants play in the neonatology
community and could become the first engineered  humanized  surfactant available
throughout  the world.  Our strategy is to build a  therapeutic  portfolio  that
addresses the range of respiratory  disorders treated in the NICU, critical care
and  hospital  settings.  Tom  brings a wealth of  operational  experiences  and
pharmaceutical  industry  relationships  that  are  essential  to  properly  and
carefully execute this strategy," continued Dr. Capetola.

Mr. Amick received a B.S. Degree in Business from Elon University. Additionally,
he has completed  graduate courses at the Darden Business School,  University of
Virginia,  the Kellogg  School of  Business,  Northwestern  University,  and the
Harvard Business School.

ABOUT DISCOVERY LABORATORIES Discovery Laboratories, Inc. is a biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases. Surfactants are compositions produced naturally in the lungs and essential for breathing. Discovery's technology produces an engineered version of natural human lung surfactant that is designed to closely mimic the essential properties of human lung surfactant. Discovery believes that through its technology, pulmonary surfactants have the potential, for the first time, to be developed into a series of respiratory therapies for critical care and other hospitalized patients where there are few or no approved therapies available. Discovery has filed a New Drug Application with the FDA for clearance to market Surfaxin(r), the Company's lead product, for the prevention of Respiratory Distress Syndrome in premature infants. Discovery is currently conducting a Phase 2 clinical trial for Acute Respiratory Distress Syndrome in adults, Phase 3 and Phase 2 clinical trials for Meconium Aspiration Syndrome in full-term infants. With aerosolized surfactant formulations, Discovery is preparing to initiate a Phase 2 trial for asthma (development name DSC-104) and a Phase 2 trial for Neonatal Pulmonary Disorders. More information about Discovery is available on the Company's Web site at www.DiscoveryLabs.com. To the extent that statements in this press release are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are the risk that financial conditions may change, risks relating to the progress of the Company's research and development, the risk that the Company will not be able to raise additional capital or enter into additional collaboration agreements (including strategic alliances for our aerosol and Surfactant Replacement Therapies), risk of delay in the Company's preparation and filing of applications for regulatory approval, risk of delay in the FDA's or other health regulatory authorities' approval of any applications filed by the Company, risks that any such regulatory authority will not approve the marketing and sale of a drug product even after acceptance of an application filed by the Company for any such drug product, risks relating to the ability of the Company's third party contract manufacturers to provide the Company with adequate supplies of drug substance and drug products for completion of any of the Company's clinical studies, other risks relating to the lack of adequate supplies of drug substance and drug product for completion of any of the Company's clinical studies, and risks relating to the development of competing therapies and/or technologies by other companies. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results. Data obtained from tests are susceptible to varying interpretations,

which may delay, limit or prevent regulatory approval. Those associated risks and others are further described in the Company's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Company Contacts: John G. Cooper, EVP and CFO Kori Beer, IR & Communications 215-340-4699